Results 21 to 30 of about 141,956 (266)
CDK4/6 inhibition in cancer: the cell cycle splicing connection
Molecular & Cellular Oncology, 2019 Cyclin-dependent kinase −4 and −6 (CDK4/6) inhibitors are currently being assessed in clinical trials for the treatment of many cancers including melanoma.
Karen E. Sheppard, Shatha AbuHammad
doaj +1 more source
TP53 and liver carcinogenesis [PDF]
Human Mutation, 2003 Primary hepatocellular carcinoma (HCC) is one of the most common malignancies and has the fourth highest mortality rate worldwide. The major risk factors, including chronic infections with the hepatitis B or C virus, are exposure to dietary aflatoxin B1(AFB1), vinyl chloride, or alcohol consumption.
Frank, Staib +4 more
openaire +2 more sources
TP53 Mutations in Human Meningiomas [PDF]
The International Journal of Biological Markers, 2002 Overexpression of p53 has been reported to play a role in the development of neoplasms of the central nervous system. Meningiomas are generally benign intracranial tumors originating from the meninges. Overexpression of the p53 protein in meningiomas and an association with histological type and recurrence has been reported.
F M, Verheijen +5 more
openaire +2 more sources
OncoImmunology, 2021 Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma with high mutation burdens but a low response rate to immune checkpoint inhibitors.
Hua You +28 more
doaj +1 more source
TP53 in Biology and Treatment of Osteosarcoma [PDF]
Cancers, 2021 The TP53 gene is mutated in 50% of human tumors. Oncogenic functions of mutant TP53 maintain tumor cell proliferation and tumor growth also in osteosarcomas. We collected data on TP53 mutations in patients to indicate which are more common and describe their role in in vitro and animal models. We also describe animal models with TP53 dysfunction, which
Kamil Jozef Synoradzki +8 more
openaire +2 more sources
Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
Nucleic Acids Research, 2023 ABSTRACT TP53 is a transcription factor that controls multiple cellular processes, including cell cycle arrest, DNA repair, and apoptosis. The relation between TP53 binding site architecture and transcriptional output is still not fully understood.
Max Trauernicht +4 more
openaire +3 more sources
Cancer Management and Research, 2022 Huafang Wang,1 Yuan Chen,2 Huijun Lin,3 Wanmao Ni,4 Qiaolei Zhang,5 Jianping Lan,1 Lai Jin1 1Cancer Center, Department of Hematology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, Zhejiang ...
Wang H +6 more
doaj
Molecular and clinical aspects of HNSCC in the Republic of Moldova
Romanian Journal of Laboratory Medicine, 2023 Introduction: Complex molecular characterization and integrated approaches in the basic research of HNSCC provide new insights into the understanding and treatment of these tumors.
Stratan Valentina +9 more
doaj +1 more source
结直肠肛门外科, 2023 [Objectives] To investigate TP53 and clinicopathological characteristics on the survival prognosis of patients with stage Ⅱ/Ⅲ colorectal cancer. [Methods] The clinical data of 57 patients with stage Ⅱ/Ⅲ colorectal cancer who were admitted to Wenzhou ...
Huang Lifeng +6 more
doaj +1 more source
Chinese Journal of Lung Cancer, 2023 Lung squamous cell carcinoma (LSCC) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases and is the second most common histological type of lung cancer.
Donglai LV +3 more
doaj +1 more source